Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 31Terminated 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3Thoracic 1

Conditions

Neoplasms 3Anemia 3Pleural Effusion, Malignant 1Pleural Effusion 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Darbepoetin alfa × Clear all
NCT00858364 2022-11-30

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Amgen

Phase 3 Terminated
2,549 enrolled 19 charts
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Pleural Effusion, Pleural Effusion, Malignant

NCT00989092 2014-01-29

Darbepoetin Alfa and Anemia of Cancer

Amgen

Phase 2 Terminated
287 enrolled 21 charts
Classical hematology

Anemia, Carcinoma, Neoplasms

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
235 enrolled 13 charts
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡